SCHEMBL31340004

SCHEMBL31340004

Cc1cnc(NCc2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc1-c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 2/20 0.46
▸ IDO1 P14902 1/20 0.45
▸ MAPT P10636 4/20 0.43
▸ MET P08581 2/20 0.43
▸ IP6K1 Q92551 1/20 0.43
▸ IP6K3 Q96PC2 1/20 0.43
▸ IP6K2 Q9UHH9 1/20 0.43
▸ LMNA P02545 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ SCD O00767 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CCR1 P32246 1/20 0.39
▸ ABCC8 Q09428 1/20 0.39
▸ KCNJ11 Q14654 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31339996 0.85 CLK1 (0.47) MAPT
SCHEMBL31340009 0.84 SCD (0.41) MAPTSCDPOLBGAA
SCHEMBL31327409 0.82 POLB (0.53) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL31339981 0.82 ALDH1A1 (0.43) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL31339943 0.77 TRPV1 (0.48) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL31339975 0.75 TRPV1 (0.53) MAPTGAAKDM4EALDH1A1
SCHEMBL31339974 0.73 GPBAR1 (0.48) MAPT
SCHEMBL21121210 0.68 MAPT (0.59) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL21163901 0.68 KMT2A (0.48) PIN1MAPTLMNAMEN1KMT2A
SCHEMBL31339966 0.68 CTSC (0.44) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF JILIN UNIVERSITY (CN) 2026-05-07 — — US disclosed
EP-4725485-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF Jilin University (CN) 2026-04-15 — — EP disclosed
CN-119285557-A CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof 吉林大学 2025-01-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124202-A1 CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF GZMB, CD74, GSDMD PIN1 4589/4885IDO1 1954/4885MAPT 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback